TRDA Entrada Therapeutics, Inc. Net earnings per share for the last 12 months

Collaboration with Vertex Pharmaceuticals is driving the growth of Entrada Therapeutics (TRDA), as evidenced by the trend in net income per share. The value of -3.82 represents the current level of the metric. Entrada Therapeutics (TRDA) leverages the Inertia platform to treat high-margin rare brain pathologies and attracts leading biochemists through a stock option system to accelerate the development of neuromuscular drugs.

TRDA Entrada Therapeutics Earnings per share for the trailing year (07/04/2022 - 11/15/2026)

Entrada Therapeutics, Inc - analytical breakdowns and key metrics (TRDA)

- stock price and consensus target price:

Stock Price Entrada Therapeutics, Inc|TRDA - Average Forecast Price

- market capitalization data:

Market Valuation Entrada Therapeutics Inc.|TRDA - Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share Entrada Therapeutics|TRDA - Accounting Value of Company|Market Value to Book Value Ratio entradatx.com|TRDA - Company Assets

- debt level and financial liquidity data:

- earnings and multiples data:

TRDA - Company Net Income|Expected Profit Entrada Therapeutics|TRDA - Price to Earnings Multiple|Projected Price to Earnings Entrada Therapeutics, Inc.|TRDA - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Entrada Therapeutics, Inc|TRDA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Entrada Therapeutics|TRDA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth entradatx.com|TRDA - Earnings per share growth this year|Earnings growth forecast for next year Entrada Therapeutics

- issuer revenue and sales details:

TRDA - Revenue and Sales Volume|Company Future Sales Volume Entrada Therapeutics, Inc.|TRDA - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Entrada Therapeutics, Inc.|TRDA - Revenue Change YoY (Last 12 Months)

Basic company analysis:entradatx.com (TRDA)

Entrada Therapeutics (TRDA) utilizes its innovative EEV platform for cellular drug delivery, creating unique therapeutic potential within the incurable disease segment. This 12-month net income per share chart digitizes the effectiveness of this strategy, dividing total net income by the number of outstanding shares to assess the real return on each equity stake, excluding dilution from new issuances.

Analysis of competing companies